183 related articles for article (PubMed ID: 12745413)
21. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
22. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
[TBL] [Abstract][Full Text] [Related]
23. Thrombocytopenia in HIV-infected drug users in the HAART era.
Burbano X; Miguez MJ; Lecusay R; Rodriguez A; Ruiz P; Morales G; Castillo G; Baum M; Shor-Posner G
Platelets; 2001 Dec; 12(8):456-61. PubMed ID: 11798394
[TBL] [Abstract][Full Text] [Related]
24. Alcohol consumption and HIV disease progression: are they related?
Samet JH; Horton NJ; Traphagen ET; Lyon SM; Freedberg KA
Alcohol Clin Exp Res; 2003 May; 27(5):862-7. PubMed ID: 12766632
[TBL] [Abstract][Full Text] [Related]
25. Treatment outcome of HAART-treated patients in a resource-limited setting: the Belgrade Cohort Study.
Jevtović D; Dragovic G; Salemović D; Ranin J; Kušić J; Marinković J; Djurković-Djaković O
Biomed Pharmacother; 2014 Apr; 68(3):391-5. PubMed ID: 24486106
[TBL] [Abstract][Full Text] [Related]
26. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
Kaufmann GR; Perrin L; Pantaleo G; Opravil M; Furrer H; Telenti A; Hirschel B; Ledergerber B; Vernazza P; Bernasconi E; Rickenbach M; Egger M; Battegay M;
Arch Intern Med; 2003 Oct; 163(18):2187-95. PubMed ID: 14557216
[TBL] [Abstract][Full Text] [Related]
27. Oral candidosis as a clinical marker of immune failure in patients with HIV/AIDS on HAART.
Gaitán-Cepeda LA; Martínez-González M; Ceballos-Salobreña A
AIDS Patient Care STDS; 2005 Feb; 19(2):70-7. PubMed ID: 15716638
[TBL] [Abstract][Full Text] [Related]
28. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART.
Collazos J; Asensi V; Cartón JA
AIDS; 2007 Apr; 21(7):835-43. PubMed ID: 17415038
[TBL] [Abstract][Full Text] [Related]
29. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
[TBL] [Abstract][Full Text] [Related]
30. A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users.
Macalino GE; Hogan JW; Mitty JA; Bazerman LB; Delong AK; Loewenthal H; Caliendo AM; Flanigan TP
AIDS; 2007 Jul; 21(11):1473-7. PubMed ID: 17589194
[TBL] [Abstract][Full Text] [Related]
31. Factors associated with virological response in HIV-infected patients failing antiretroviral therapy: a prospective cohort study.
Fournier S; Chaffaut C; Maillard A; Loze B; Lascoux C; Gérard L; Timsit J; David F; Bergmann JF; Oksenhendler E; Sereni D; Chevret S; Molina JM
HIV Med; 2005 Mar; 6(2):129-34. PubMed ID: 15807719
[TBL] [Abstract][Full Text] [Related]
32. HIV-related wasting in HIV-infected drug users in the era of highly active antiretroviral therapy.
Campa A; Yang Z; Lai S; Xue L; Phillips JC; Sales S; Page JB; Baum MK
Clin Infect Dis; 2005 Oct; 41(8):1179-85. PubMed ID: 16163638
[TBL] [Abstract][Full Text] [Related]
33. Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection.
Kaufmann GR; Khanna N; Weber R; Perrin L; Furrer H; Cavassini M; Ledergerber B; Vernazza P; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
Antivir Ther; 2004 Apr; 9(2):263-74. PubMed ID: 15134189
[TBL] [Abstract][Full Text] [Related]
34. Autoimmune diseases-related arthritis in HIV-infected patients in the era of highly active antiretroviral therapy.
Yang JJ; Tsai MS; Sun HY; Hsieh SM; Chen MY; Sheng WH; Chang SC
J Microbiol Immunol Infect; 2015 Apr; 48(2):130-6. PubMed ID: 24064287
[TBL] [Abstract][Full Text] [Related]
35. Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial.
Lalezari JP; Beal JA; Ruane PJ; Cohen CJ; Jacobson EL; Sundin D; Leong WP; Raffanti SP; Wheeler DA; Anderson RD; Keiser P; Schrader SR; Goodgame JC; Steinhart CR; Murphy RL; Wolin MJ; Smith KA
HIV Clin Trials; 2000; 1(3):1-15. PubMed ID: 11590500
[TBL] [Abstract][Full Text] [Related]
36. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
[TBL] [Abstract][Full Text] [Related]
37. Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study.
Sabin CA; Hill T; Lampe F; Matthias R; Bhagani S; Gilson R; Youle MS; Johnson MA; Fisher M; Scullard G; Easterbrook P; Gazzard B; Phillips AN;
BMJ; 2005 Mar; 330(7493):695. PubMed ID: 15749728
[TBL] [Abstract][Full Text] [Related]
38. Hazardous and harmful use of alcohol and/or other drugs and health status among South African patients attending HIV clinics.
Kader R; Seedat S; Govender R; Koch JR; Parry CD
AIDS Behav; 2014 Mar; 18(3):525-34. PubMed ID: 23921585
[TBL] [Abstract][Full Text] [Related]
39. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
[TBL] [Abstract][Full Text] [Related]
40. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy.
Kohli R; Lo Y; Howard AA; Buono D; Floris-Moore M; Klein RS; Schoenbaum EE
Clin Infect Dis; 2005 Sep; 41(6):864-72. PubMed ID: 16107987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
